Seventure Partners

Reelevant is a customer experience solution focused on hyper-personalization, helping brands reconnect with their customers at critical moments. Founded in 2016, the company enhances the last mile of customer experience by translating data into relevant, real-time content tailored to individual customer moments across all digital touchpoints. By leveraging its email intelligence technology, Reelevant improves email marketing performance through the collection and analysis of real-time data, ensuring that businesses can engage customers effectively and maximize customer lifetime value. Its clientele includes notable brands such as Carrefour, Décathlon, L'Oréal, and Leroy Merlin.

Flexvelop is a fintech company based in Hamburg that specializes in providing an embedded payment solution for financing business equipment. By enabling business customers to rent new equipment that is fully insured, Flexvelop allows for the flexibility to either purchase or return the equipment at any time. This approach offers a swift and adaptable alternative to traditional leasing processes, utilizing patented in-house financing technology. Flexvelop's services are designed to support startups and medium-sized enterprises by facilitating the acquisition of equipment from various suppliers quickly and efficiently. In addition to enhancing operational capabilities, Flexvelop promotes a sustainable circular economy by encouraging the use of the latest technology while minimizing waste.

SeaWeed Concept is a marine biotechnology company that specializes in harnessing the potential of seaweed to supply high-quality, sustainable ingredients to diverse industries. The company's patented preservation technologies allow seaweed to be stored for extended periods, ensuring a consistent, year-round supply for sectors such as food, cosmetics, and agriculture.

Ekstere is an online marketplace that specializes in the sale of pre-owned electric bicycles. The company offers a curated selection of reconditioned e-bikes that come with certification, ensuring quality and reliability for consumers. By prioritizing sustainability and transparency, Ekstere enables customers to purchase electric bicycles at reasonable prices, thereby promoting the adoption of eco-friendly transportation solutions. The platform targets consumers who value verified quality and seeks to make electric mobility accessible to a broader audience.

Anybuddy is a leading sports booking marketplace in France, specializing in racket sports. The company has developed a sports application that facilitates the discovery of players and venues for football and tennis matches. Its platform provides users with access to hundreds of clubs, allowing them to reserve and pay for bookings without the need for a license or subscription. By offering a variety of quality tennis courts and multiple play surfaces, Anybuddy enables users to make reservations directly through the application at competitive prices.

Karmen provides non-dilutive financing solutions designed to help digital businesses access capital efficiently and flexibly. The company specializes in revenue-based financing, allowing companies to secure funds for diverse needs such as customer acquisition, recruitment, and inventory financing. Karmen's platform features a streamlined online process that integrates with existing tools and employs secured API connections to analyze data. This functionality enables businesses to receive approval for funding in a short timeframe, complemented by detailed performance dashboards that enhance financial visibility and decision-making.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Bsport solution is a software platform for boutique fitness studios. From marketing, live classes, group class and appointment management, invoicing and teacher management, they help studios and boutique fitness manage their activities while creating new revenue streams. Everyone can access every tool and feature without the need for multiple add-ons or integrations by using its custom all-inclusive software. Whatever its priorities and preferences are, its platform is tailored to fit all business types and industries.

Syroco is a scientific and technical laboratory based in Marseille, France, focused on enhancing efficiency in the transportation and energy sectors. Established in 2019, the company specializes in innovative solutions, including the development of a speed craft aimed at breaking sailing speed records. Syroco was founded by a diverse team, including a kitesurfer, a two-time world sailing record holder, and experts from startup and naval architecture backgrounds. The company adopts a unique approach characterized by "moonshot challenges," which encourage technological advancements to address significant industry hurdles. Additionally, Syroco develops modeling software that utilizes data and artificial intelligence to create digital twins, thereby optimizing operational and energy efficiency within maritime transportation. This forward-thinking approach positions Syroco as a pivotal player in supporting the sustainable transition of energy sectors while engaging collaboratively with industry stakeholders.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Dashbook is a publishing house that facilitates collaborative book creation and distribution. It empowers authors by providing a platform to publish their works, making them accessible to the public.

Developer of SaaS-based internal help desk software designed to streamline employee support. The company's software integrates with existing communication channels, automates manual tasks and provides advanced analytics by centralizing employee data and quantifying KPIs, enabling organizations to enhance employee experience, improve operational efficiency and reduce support costs.

Otoqi is a company that develops an automotive management platform aimed at enhancing the entire lifecycle of vehicles. Its innovative technology offers solutions for sales, after-sales, and shared mobility, enabling mobility operators to navigate the complexities of vehicle logistics. Otoqi's platform facilitates instant ordering and provides real-time visibility and control in the buying process for both new and used cars. Additionally, it streamlines operations by efficiently transferring vehicles between various sites, agencies, and partners. The company also offers comprehensive vehicle testing and after-sales services, ensuring that customers can access a full range of solutions tailored to their needs.

Aenitis Technologies is a French start-up founded in July 2014 by researchers Mauricio Hoyos and Jean-Luc Aider from the CNRS. The company specializes in the development of innovative medical devices that address challenges in cell therapy preparation and bioprocessing. Aenitis Technologies focuses on solutions for cell sorting, washing, and isolation, utilizing acoustophoresis technologies to enhance the efficiency of these processes. With an emphasis on revolutionizing practices in public health, Aenitis Technologies aims to establish itself as a world leader in the separation and filtration of biological elements, providing vital support to cell therapy units and blood banks in the healthcare industry.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Sinay is a company that specializes in providing solutions for stakeholders in the maritime sector through the collection and analysis of maritime data. It has developed a big data platform that focuses on studying the marine environment, integrating advanced technologies to enhance maritime activities. This platform offers maritime analytics, facilitates easy maritime surveys, and provides user-friendly dashboards. By enabling maritime industries to manage increasing volumes of data and conduct complex analyses, Sinay supports stakeholders in making informed decisions and improving efficiency within the sector.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

ID5 is a company focused on enhancing online advertising for consumers, media owners, and advertisers, with a primary aim of helping publishers achieve sustainable revenue growth. It offers a transparent and privacy-compliant identity infrastructure that replaces third-party cookies and mobile advertising IDs. This infrastructure improves user recognition and match rates, providing a stable, consented, and encrypted user ID. By doing so, ID5 enables publishers to better monetize their audiences and allows advertisers to execute effective and measurable campaigns. Additionally, the company's centralized identification synchronization platform addresses inefficiencies in website campaign performance by managing cookie synchronization, ensuring privacy compliance, and optimizing consent management, thus enhancing the overall user experience and operational efficiency for publishers and data providers.

Peptobiotics is a biotechnology startup focused on livestock disease prevention through innovative synthetic biology solutions. The company specializes in the development of recombinant custom peptides cultivated from synthetic microorganisms, which serve as antibiotic alternatives for promoting animal health and growth. By providing farmers and breeders with effective tools to protect livestock against pathogens, Peptobiotics aims to enhance agricultural productivity while ensuring humane and sustainable practices. The company’s approach addresses the critical need for disease prevention in livestock without contributing to antibiotic resistance, thereby fostering a more responsible and sustainable agricultural ecosystem.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Starfish Bioscience is focused on developing microbiological solutions aimed at enhancing agricultural and viticultural practices. The company seeks to regenerate soils by restoring their microbiomes, which in turn improves soil health and increases crop yields. By offering analysis of soil microbiomes and tailored solutions, Starfish Bioscience enables farmers to achieve greater sustainability and productivity while minimizing their environmental impact. The company's commitment to innovation is driven by a desire to address the future challenges of global agriculture, ultimately contributing to the well-being of humanity and the preservation of the planet.

Nimble Science Ltd. is a digital health company focused on revolutionizing gastrointestinal (GI) health through its innovative SIMBA capsule technology. This end-to-end platform facilitates multi-omic mapping of the GI tract, allowing for the passive sampling of small bowel luminal fluid. By leveraging this advanced sampling method, Nimble Science provides precision datasets that offer valuable insights into GI health, thereby transforming the diagnosis and treatment of gastrointestinal conditions. The company's approach enables healthcare providers to directly sample and analyze targeted regions of the GI tract, marking a significant advancement in the understanding and management of GI health.

Nexess SAS is a French company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Established in 2006 and headquartered in Mougins, France, with an additional office in Paris, Nexess offers a comprehensive range of products, including the NexLink software platform, which enhances security and productivity. The company also provides a variety of identification products such as personal security badges, RFID tags, and mobile devices, as well as smart camera systems that enable autonomous image analysis and real-time data transmission. Its solutions are designed for applications like hazardous product traceability, secure equipment management, site localization, and access detection in hazardous zones. Nexess aims to support digital transformation projects through its innovative technology, enhancing productivity, quality, and security for its clients.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Pitchy is a video creation platform that offers a software-as-a-service (SaaS) solution for users to produce professional interactive videos without needing technical skills. By utilizing ready-to-use templates designed with Adobe After Effects, users can easily customize videos for various scenarios, such as investor pitches or product descriptions. The platform allows users to create videos by simply selecting a template, adding their own text, images, logos, and videos, and completing the project in minutes. Clients have the option to either purchase the final video or subscribe for a monthly fee, which includes hosting the video on Pitchy's own account. With its focus on user-friendly design and efficient video production, Pitchy aims to help businesses enhance their marketing efforts and drive customer engagement.

Allozymes is a prominent deep technology company that specializes in the application of ultrahigh-throughput microfluidics technology to enhance the evolution and development of enzymes. The company focuses on creating sensitive and accurate assays for enzymatic reactions, utilizing proprietary microfluidic chips and proteomics technologies. Allozymes' platform integrates molecular biology and process engineering to produce high-purity enzymes tailored for specific applications. This innovative approach enables clients to expedite custom enzyme development and to create novel, sustainable natural products, positioning Allozymes as a leader in the enzyme development sector.

Hepster is an InsurTech company specializing in the development of customized insurance products that are seamlessly integrated into digital processes and systems. The company operates primarily on a B2B model, which is enhanced by a B2C webshop. Hepster's core strength lies in its fully API-driven, cloud-based, and modular insurance solutions, enabling rapid construction and deployment of digital insurance products tailored to the specific needs of its partners. Its diverse product portfolio encompasses insurance for bicycles, e-bikes, electronics, pets, and sports equipment, offering clients in the insurance value chain a comprehensive end-to-end experience.

Sekoia.io is a developer of an advanced security operations center (SOC) platform that equips security teams with tools to effectively identify and respond to significant cyber threats across their entire attack surface. The platform integrates real-time detection and automation, allowing teams to manage the complexities and high volumes of security incidents while reducing false positives. By continuously analyzing emerging threats and implementing strategic responses, Sekoia.io enables organizations to enhance their security posture and respond to threats more swiftly and reliably than traditional security information and event management (SIEM) systems. This proactive approach ensures that clients remain informed and prepared against evolving cyber risks.

Sinay is a company that specializes in providing solutions for stakeholders in the maritime sector through the collection and analysis of maritime data. It has developed a big data platform that focuses on studying the marine environment, integrating advanced technologies to enhance maritime activities. This platform offers maritime analytics, facilitates easy maritime surveys, and provides user-friendly dashboards. By enabling maritime industries to manage increasing volumes of data and conduct complex analyses, Sinay supports stakeholders in making informed decisions and improving efficiency within the sector.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Bsport solution is a software platform for boutique fitness studios. From marketing, live classes, group class and appointment management, invoicing and teacher management, they help studios and boutique fitness manage their activities while creating new revenue streams. Everyone can access every tool and feature without the need for multiple add-ons or integrations by using its custom all-inclusive software. Whatever its priorities and preferences are, its platform is tailored to fit all business types and industries.

Graphite Innovation & Technologies is a materials engineering firm dedicated to developing innovative and sustainable smart coating solutions for the shipping industry. By leveraging nanotechnology, the company produces environmentally friendly paints designed to enhance the efficiency of ocean-going vessels, significantly reducing fuel consumption and greenhouse gas emissions. GIT's advanced marine coatings are hydrophobic and exceptionally hard, preventing marine life from adhering to hull surfaces, thereby minimizing drag as vessels navigate through water. With a growing portfolio of ocean-going ships utilizing its technology, the company is poised to expand production globally. GIT distinguishes itself in the marine coatings market by offering a full suite of products that do not rely on harmful leaching chemicals, positioning itself as a disruptive force committed to fostering a more sustainable maritime future.

Glopal is a company that specializes in enhancing e-commerce capabilities for businesses seeking to expand internationally. It offers a comprehensive platform that includes localization, marketing, international shipping, and management of duties and taxes, ensuring a seamless shopping experience for customers across different markets. By utilizing automated localization tools and international SEO strategies, Glopal enables merchants to reach global buyers in their preferred language and currency. Additionally, its marketing portal is designed to drive multi-channel traffic, helping businesses generate incremental sales and effectively attract and convert international customers. Through these services, Glopal aims to facilitate the discovery of new international buyers while providing an optimized shopping experience tailored to diverse markets.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Flexvelop is a fintech company based in Hamburg that specializes in providing an embedded payment solution for financing business equipment. By enabling business customers to rent new equipment that is fully insured, Flexvelop allows for the flexibility to either purchase or return the equipment at any time. This approach offers a swift and adaptable alternative to traditional leasing processes, utilizing patented in-house financing technology. Flexvelop's services are designed to support startups and medium-sized enterprises by facilitating the acquisition of equipment from various suppliers quickly and efficiently. In addition to enhancing operational capabilities, Flexvelop promotes a sustainable circular economy by encouraging the use of the latest technology while minimizing waste.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Mediarithmics is a cloud-based marketing technology company headquartered in Fontenay-sous-Bois, France. Founded in 2011, it offers a next-generation customer data platform (CDP) that integrates data management and marketing automation functionalities. The platform allows brands to manage retargeting campaigns across multiple devices, including mobiles, tablets, and PCs, while enabling agencies to handle clients' real-time bidding (RTB) and email campaigns through a unified tool. Mediarithmics supports the creation of data alliances to ensure data security and compliance with regulations, facilitating the collection and segmentation of customer data for real-time, multi-channel campaign activation. Additionally, the platform allows clients to incorporate their own algorithms for enhanced personalization in marketing strategies, focusing on consumer engagement and effective measurement of campaign performance.

BAOUW / Outdoor Organic Nutrition specializes in the production of organic food products designed for athletes and health-conscious individuals. The company offers a range of items, including organic nutrition bars, purees, energy nuts, and various accessories. Emphasizing natural ingredients, BAOUW focuses on unprocessed components that provide beneficial lipids, vegan proteins, and natural fruit sugar. Their products are formulated to deliver long-lasting energy while being easy to digest and convenient for on-the-go consumption. Through their commitment to gourmet, responsible, and efficient nutrition, BAOUW aims to support individuals in maintaining their health and performance.

Citalid is a cybersecurity company that specializes in assessing and quantifying cyber risks for enterprises and insurers. The company has developed an advanced platform that evaluates the likelihood of cyberattacks and estimates their potential financial impacts. By integrating Cyber Threat Intelligence with risk quantification, Citalid offers a comprehensive view of potential threats and simulates various scenarios to model their financial consequences. This enables organizations to make informed decisions about their cybersecurity strategies and prepare effectively. Additionally, Citalid provides tailored security and insurance recommendations, helping businesses implement actionable measures to mitigate risks. For insurers, the platform enhances the understanding of portfolio exposure to cyber threats and supports customers in making smarter decisions regarding cyber risk management.

Clinical Microbiomics is an independent contract research organization dedicated to advancing microbiome research across various domains, including human, animal, plant, and soil microbiomes. The company offers comprehensive microbiome research services, which encompass clinical trial consulting, sequencing, and complex bioinformatics. With a team of skilled molecular biologists and bioinformatics specialists, Clinical Microbiomics focuses on the role of the microbiome in various clinical conditions such as diabetes, obesity, and inflammatory bowel diseases. Their approach emphasizes collaboration, ensuring that microbiome experts guide partners through the study process, from experimental design to final analysis. By thoroughly reviewing findings with clients, Clinical Microbiomics aims to provide actionable insights that enhance research outcomes and promote the application of microbiomes in treating diseases and improving agricultural practices.

Soan is an online payment solution that provides a comprehensive suite of tools designed to facilitate the success of freelance projects. The company's platform enables users to manage their finances effectively, offering features such as an integrated payment system for invoicing, automated bill reminders, and other financial management tools. By streamlining these processes, Soan supports businesses in maintaining better control over their financial operations and enhancing their overall productivity.

Standing Ovation specializes in developing vegan cheese alternatives that closely mimic the taste and texture of traditional dairy cheese. The company employs scientific methods to create animal-free and environmentally friendly cheese products, utilizing protein-producing microbes that are fed with plant-based sugars in a fermentation process reminiscent of traditional cheesemaking. This innovative approach not only offers a healthier option for consumers but also aligns with the growing demand for sustainable and plant-based food choices.

Sentryc is a brand protection firm that specializes in safeguarding companies and their products from online piracy and brand abuse. Utilizing proprietary software, Sentryc provides a digital solution for monitoring online marketplaces to detect and address product counterfeiting. The company's platform automates the scanning of websites for products, allowing it to identify and document potential counterfeits efficiently. Additionally, Sentryc helps clients by automatically reporting these infringing listings for deletion, thereby facilitating the protection of brand assets and ensuring a secure online presence for its clients.

Ideel is a subscription management platform that streamlines the process of managing various subscriptions for both businesses and consumers. It offers a user-friendly interface where users can view all their subscription expenses, receive notifications for tariff changes, and track renewal dates or trial periods. The platform simplifies the cancellation and pausing of subscriptions, allowing users to manage these tasks with a single click. Ideel also provides tools for optimizing contracts and monitoring expenses across a range of services, including media, streaming, telephony, electricity, and insurance. By automating the management of subscriptions, Ideel helps users save time and reduce costs without the hassle of navigating complex formalities.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Jolimoi is a skincare products company that specializes in beauty and makeup merchandise. The company's extensive catalog includes face care products, hair care products, makeup items, oils, fragrances, and various accessories designed for both men and women. Jolimoi emphasizes personalized recommendations, tailoring suggestions based on individual preferences shared by customers. This approach enhances the shopping experience by helping users find products that best suit their needs.

One.bio is an emerging biotechnology company spun out from UC Davis, specializing in the development of naturally-derived oligosaccharides for food, agriculture, and biopharmaceutical applications. Utilizing proprietary technology, the company creates novel oligosaccharides from natural products aimed at positively influencing the microbiome and enhancing immune function. One.bio's innovative ingredients provide clients with access to prebiotics and therapies that support both human and animal health, positioning the company as a significant player in the fields of nutrition and longevity.

Geovelo is a company that develops a free navigation application designed to assist cyclists with route planning and guidance. The app provides directions through voice prompts, maps, or compass features, helping users discover rides, plan trips, and find reliable and secure routes. Additionally, it fosters community engagement by allowing users to join groups and participate in challenges, thereby promoting daily cycling.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Hepster is an InsurTech company specializing in the development of customized insurance products that are seamlessly integrated into digital processes and systems. The company operates primarily on a B2B model, which is enhanced by a B2C webshop. Hepster's core strength lies in its fully API-driven, cloud-based, and modular insurance solutions, enabling rapid construction and deployment of digital insurance products tailored to the specific needs of its partners. Its diverse product portfolio encompasses insurance for bicycles, e-bikes, electronics, pets, and sports equipment, offering clients in the insurance value chain a comprehensive end-to-end experience.

Hardloop is an online retailer based in Paris, France, specializing in sports products and adventure gear. Established in 2014, the company offers a diverse range of equipment and clothing for various outdoor activities, including hiking, trail running, skiing, climbing, and swimming. Through its platform, Hardloop provides sports enthusiasts with access to a wide selection of shoes, gloves, bottles, and other essential accessories from numerous international brands, catering to the needs of those seeking new adventures in sports.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Ecto, established in 2013 at Harvard Innovation Labs by Dmitry Kozachenok and James Webb, specializes in developing advanced technology that intersects data and biology to enhance aquaculture efficiency and sustainability globally. Headquartered in Boston with offices in Atlanta and Stavanger, Norway, the company collaborates with farmers worldwide, offering a farm management platform that integrates operational data with molecular biology. This enables real-time insights, disease detection, and prevention, ultimately streamlining production processes and creating healthier protein servings. To date, Ecto's solutions have facilitated an additional 51.5 million healthy servings of protein. The company has been backed by competitive research grants from the US National Science Foundation, US Department of Agriculture, and Innovation Norway.

CattleEye, founded in 2019 in the United States, specializes in manufacturing autonomous livestock monitoring systems. The company offers a cloud-based artificial intelligence platform that interprets and analyzes visual imagery of livestock using web cameras and other vision detection equipment. This solution identifies and measures various indicators such as gait, mobility scores, and other behavioral signs, providing farmers with comprehensive insights into the performance and welfare of their cows.

Proteon Pharmaceuticals Ltd. is a biotechnology company based in Lodz, Poland, founded in 2005. The company specializes in developing bacteriophage-based products aimed at enhancing animal and human health while promoting environmental sustainability. Proteon Pharmaceuticals employs precision biology to create solutions that protect the microbiome, significantly reducing the reliance on antibiotics and addressing the challenges posed by antimicrobial resistance. Their product pipeline includes innovative applications for poultry, aquaculture, and dairy sectors, focusing on improving performance, food safety, and preventing economically significant bacterial diseases. Additionally, the company offers contract services for high-throughput screening of chemical libraries, as well as ADME/Tox and immunotoxicity testing of therapeutic substances using in vitro cell cultures.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Ecto, established in 2013 at Harvard Innovation Labs by Dmitry Kozachenok and James Webb, specializes in developing advanced technology that intersects data and biology to enhance aquaculture efficiency and sustainability globally. Headquartered in Boston with offices in Atlanta and Stavanger, Norway, the company collaborates with farmers worldwide, offering a farm management platform that integrates operational data with molecular biology. This enables real-time insights, disease detection, and prevention, ultimately streamlining production processes and creating healthier protein servings. To date, Ecto's solutions have facilitated an additional 51.5 million healthy servings of protein. The company has been backed by competitive research grants from the US National Science Foundation, US Department of Agriculture, and Innovation Norway.

Otoqi is a company that develops an automotive management platform aimed at enhancing the entire lifecycle of vehicles. Its innovative technology offers solutions for sales, after-sales, and shared mobility, enabling mobility operators to navigate the complexities of vehicle logistics. Otoqi's platform facilitates instant ordering and provides real-time visibility and control in the buying process for both new and used cars. Additionally, it streamlines operations by efficiently transferring vehicles between various sites, agencies, and partners. The company also offers comprehensive vehicle testing and after-sales services, ensuring that customers can access a full range of solutions tailored to their needs.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing a digital therapeutic aimed at treating myopia, commonly known as shortsightedness. This condition impacts approximately one in three individuals globally and has seen a significant rise in prevalence over the past two decades. The company's innovative approach involves delivering light stimulation to specific photosensitive cells in the retina, which helps modulate dopamine levels—a neurotransmitter crucial for regulating eye growth. By focusing on children and adolescents, Dopavision aims to create a clinically validated therapy that can effectively slow myopia progression. The therapeutic solution is designed to be seamlessly integrated with smartphone technology, allowing for an accessible and user-friendly treatment option.

SportEasy is a management platform designed for amateur sports teams, launched in France in 2011. The application facilitates the organization of games and practices, enabling coaches to effectively manage their teams and communicate with players. It includes features for capturing and analyzing statistics, as well as social tools that allow players to engage with one another, such as voting for the player of the game, participating in private forums, and sharing photos. Available on both web and mobile platforms, SportEasy supports users in French and English. While the core app is free, premium plans for teams and clubs were set to be introduced in early 2015. The platform aims to streamline administrative tasks, allowing coaches, managers, and players to focus more on the sport itself.

Cytoki Pharma ApS is a biotechnology company based in Værløse, Denmark, founded in 2019. The company is focused on developing innovative treatments for diseases with significant unmet medical needs, particularly those related to epithelial injuries. As a pre-clinical entity, Cytoki Pharma's lead program centers on an engineered long-acting IL-22 protein, which has been licensed from a major pharmaceutical company. IL-22 plays a crucial role in the immune response, acting as a signal for tissue survival and repair following injury. By harnessing the therapeutic potential of this cytokine, Cytoki Pharma aims to create effective solutions for organ injuries and improve patient outcomes in conditions that currently lack adequate treatment options.

Expensya SAS is a Paris-based company specializing in multi-platform expense management software solutions. Founded in 2015, the company provides a web and mobile application designed to automate the entire process of expense report management, from receipt handling to archiving. The platform incorporates advanced technologies, including Cloud computing, Artificial Intelligence, and Machine Learning, to enhance efficiency and streamline workflows. Expensya's application is compatible with various devices, including Android, iOS, and Windows phones, and supports eight languages while adapting to local accounting regulations in approximately fifty countries. Its features include expense management, data export, accountant integration, approval workflows, and a statistics module, making it a comprehensive tool for businesses seeking to simplify and secure their expense reporting processes.

PEP-Therapy is a biotechnology company specializing in the development of innovative peptide-based therapies aimed at treating severe diseases, with a primary emphasis on cancer. The company focuses on creating Cell Penetrating and Interfering Peptides, which are designed for intracellular delivery of targeted treatments. These peptides effectively penetrate cell membranes to block crucial intracellular protein-protein interactions, thereby inhibiting important pathogenic mechanisms associated with various diseases. By harnessing the potential of these active compounds, PEP-Therapy aims to advance therapeutic options in oncology and beyond.

Foodsmart is a digital nutrition platform focused on enhancing health outcomes through personalized dietary recommendations. The company aims to support individuals dealing with chronic diseases and food insecurity by collaborating with health plans and healthcare providers. Its online telehealth application offers real-time guidance across various settings, including homes, workplaces, grocery stores, and restaurants. This comprehensive approach enables users to make healthier food choices and select recipes that can mitigate chronic health issues, thereby promoting overall well-being. By providing access to affordable and tailored healthy eating options, Foodsmart strives to empower individuals to improve their nutrition and health.

Hepster is an InsurTech company specializing in the development of customized insurance products that are seamlessly integrated into digital processes and systems. The company operates primarily on a B2B model, which is enhanced by a B2C webshop. Hepster's core strength lies in its fully API-driven, cloud-based, and modular insurance solutions, enabling rapid construction and deployment of digital insurance products tailored to the specific needs of its partners. Its diverse product portfolio encompasses insurance for bicycles, e-bikes, electronics, pets, and sports equipment, offering clients in the insurance value chain a comprehensive end-to-end experience.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Wealthpilot GmbH is a Munich-based company founded in 2017 that specializes in providing an online platform designed for investment advisors. The company aims to democratize wealth management, allowing individuals to take control of their financial lives and achieve their financial goals. Wealthpilot combines user-friendly technology with professional personal advice across a range of financial assets. Its Software-as-a-Service platform facilitates the automatic analysis and planning of various asset types, enabling advisors to offer data-driven, personalized wealth management services. By leveraging efficient cloud-based software, Wealthpilot enhances the capabilities of asset managers, streamlining processes and significantly reducing the time required to manage client assets effectively.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Dermala Inc. is a consumer dermatology company based in San Diego, California, that focuses on developing treatments for chronic skin diseases through the understanding of the human microbiome. Founded in 2014, Dermala creates personalized, clinically validated solutions for conditions such as acne and eczema, incorporating both topical and oral treatments. The company's FOBO Kit includes prebiotics and microbiome metabolites designed to eliminate acne-causing bacteria while promoting beneficial bacteria on the skin. Additionally, Dermala offers pre-medicated pads that target harmful bacteria and enhance skin health. Their approach also features a proprietary application that utilizes data analytics, machine learning, and artificial intelligence to help users track treatment outcomes and optimize their skincare regimen. Dermala’s products are available for purchase through its website, enabling individuals to effectively manage their skin health.

Animab is a biotechnology company focused on enhancing livestock health through innovative solutions. The company specializes in developing monoclonal antibodies that mimic secretory IgA, a natural antibody found in colostrum and milk, to protect nursing animals. Animab's technology targets specific intestinal pathogens in livestock, particularly during the critical post-weaning stage for piglets, without disrupting the healthy microbiome. This approach aims to improve animal health, reduce costs, and promote sustainability in livestock production.

Federation Bio Inc., established in 2018 and headquartered in South San Francisco, California, specializes in the development of microbial therapeutics targeting diseases where the human microbiome holds curative potential. The company's platforms focus on secondary hyperoxaluria and explore treatments for metabolic disorders, immune diseases, and cancer. Federation Bio's approach involves leveraging naturally occurring or engineered bacteria alongside a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses.

LARQ, Inc. is a company that manufactures and sells self-cleaning water bottles and water purification systems. Founded in 2017 and based in Foster City, California, LARQ utilizes advanced UV-C LED technology to eliminate bio-contaminants, including germs, bacteria, and protozoa, from both the water and the bottle itself. This innovative approach not only ensures safe drinking water but also promotes sustainability and convenience for users. The company's products are available for purchase online, making it easier for individuals to access pristine drinking water wherever they may be.

Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

Clim8 is a company that specializes in intelligent wearable technology, focusing on personalized thermal regulation in smart clothing. Founded in late 2015 by three co-founders, Clim8 aims to bridge the gap between the textile and digital industries by offering an innovative solution that not only tracks user activity but also actively manages comfort based on individual needs. The technology integrates tiny sensors and a detachable battery pack within the thermal layer of clothing, allowing it to monitor and analyze the wearer's body temperature. By responding to the collected data, Clim8's system delivers the appropriate amount of heat, enabling users to customize their comfort levels in various climatic conditions.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

TransferGo Ltd., established in 2012 and headquartered in London, specializes in international money transfers. It offers affordable, secure, and swift personal and commercial money transfer services, primarily targeting migrant workers sending funds to their families abroad. The company operates as a licensed and authorized payment institution, regulated by the Financial Conduct Authority (FCA) and supervised by Her Majesty's Revenue and Customs (HMRC). TransferGo charges a fixed fee per transaction, along with a currency conversion fee ranging from 0.6% to 1.5%. Its digital account-to-account business model enables users to transfer money overseas with same-day delivery, making it an efficient and cost-effective solution for both individuals and businesses.

Saagie is a company specializing in big data analytics, focusing on DataOps Orchestration to streamline and expedite analytic projects. Its platform unifies people, processes, and technology, allowing organizations to transform raw data into actionable insights within weeks. Saagie's approach emphasizes rapid time-to-value and is designed to be open, featuring isolated containers and robust network engineering. The company prioritizes security and governance, ensuring trust, privacy, and traceability in analytic projects. Saagie's platform integrates seamlessly with both open-source and commercial technologies, catering to a variety of Big Data, AI, and analytics use cases. By providing a Plug and Play Orchestrator for DataOps, Saagie empowers businesses to leverage artificial intelligence and big data effectively, enhancing their competitive edge across diverse industries.

MycoTechnology is a food technology company based in Aurora, Colorado, that specializes in utilizing fungi-based food-processing platforms to enhance the flavor and nutritional value of agricultural products. Incorporated in 2013, the company addresses challenges in the food, beverage, and flavor industries through innovative solutions. One of its key products, ClearTaste, is an all-natural, GMO-free, organic bitter blocker that is both Kosher and Halal certified, designed to improve the flavor profile of various agricultural offerings. Additionally, MycoTechnology engages in the fermentation of agricultural products using gourmet fungi, producing items such as myceliated chocolate and enhanced coffee beans. The company also develops and licenses technology aimed at naturally improving the flavor characteristics of robusta and arabica coffee, thereby enabling food producers to incorporate healthier ingredients and strengthen brand association.

ViroVet is an innovative company focused on developing advanced technologies to combat viral diseases in livestock. Its product pipeline includes antiviral drugs targeting respiratory disease complexes and novel vaccines for swine viral infections. Given the substantial economic impact of viral diseases, which cost the livestock industry billions annually, ViroVet aims to provide effective solutions that can be used independently or alongside existing vaccines and biosecurity measures. The company addresses the growing demand for animal protein amid increasing global population and livestock density, as well as climate change challenges that heighten the risk of viral outbreaks. ViroVet has garnered support from key opinion leaders in livestock medicine, who recognize the potential of its products to transform the industry, notably by reducing antibiotic usage and enhancing overall animal health and productivity.

One.bio is an emerging biotechnology company spun out from UC Davis, specializing in the development of naturally-derived oligosaccharides for food, agriculture, and biopharmaceutical applications. Utilizing proprietary technology, the company creates novel oligosaccharides from natural products aimed at positively influencing the microbiome and enhancing immune function. One.bio's innovative ingredients provide clients with access to prebiotics and therapies that support both human and animal health, positioning the company as a significant player in the fields of nutrition and longevity.

MOVE 'N SEE provides digital tools and an auto-follow camera for individual sports, team sports, and arena use. It provides attentive customer service, technological excellence, and an insatiable passion for sports, theater, and video.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

NovoBind is an integrated animal health company focused on developing next-generation biologics to address significant pathogens that impact food safety and livestock production. By targeting specific bacteria, viruses, and parasites that lead to intestinal ailments in livestock, aquaculture, and pets, NovoBind aims to combat the growing resistance to traditional anti-infectives and reduce harmful environmental residues. The company's innovative solutions are designed to mitigate the production losses exceeding $1 billion annually caused by these pathogens, thereby enhancing efficiency and sustainability in the animal sector.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Hardloop is an online retailer based in Paris, France, specializing in sports products and adventure gear. Established in 2014, the company offers a diverse range of equipment and clothing for various outdoor activities, including hiking, trail running, skiing, climbing, and swimming. Through its platform, Hardloop provides sports enthusiasts with access to a wide selection of shoes, gloves, bottles, and other essential accessories from numerous international brands, catering to the needs of those seeking new adventures in sports.

TIBOT Technologies SAS, founded in May 2016 and located in Cesson-Sévigné, France, specializes in designing and developing robotic solutions for poultry farming. The company aims to enhance the daily operations of poultry farmers by providing innovative tools that improve animal welfare and profitability. Its key products include the Spoutnic, an assistant robot that helps with various tasks, and Spoutnic NAV, which autonomously scrapes, drinks, and feeds poultry. TIBOT Technologies focuses on reducing the incidence of eggs being laid on the ground, thereby increasing the hatching rate and improving both working conditions for farmers and the overall welfare of the animals. Through its technologies, TIBOT strives to simplify poultry farming practices and make them more efficient.

FeetMe is a digital health company that specializes in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative footwear products equipped with connected insoles that analyze patients' mobility and posture in real time. By integrating pressure sensors and motion algorithms, FeetMe's technology provides valuable insights into gait patterns and movement disorders. This enables healthcare professionals to enhance patient care, monitor disease progression, and optimize treatment plans. FeetMe's focus on delivering relevant digital biomarkers supports clinical research and aims to improve the quality of life for individuals facing mobility challenges.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.